Patents Examined by Sahar Javanmard
  • Method of treating chronic kidney disease
    Patent number: 10898459
    Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: January 26, 2021
    Assignee: Panion & BF Biotech Inc.
    Inventors: Keith Chan, Winston Town
  • Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
    Patent number: 10898462
    Abstract: The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: January 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo
  • Medical treatments based on anamorelin
    Patent number: 10894041
    Abstract: Methods of treating cancer related conditions using anamorelin are described.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 19, 2021
    Assignee: Helsinn Healthcare SA
    Inventors: William Mann, John Friend, William Polvino, Suzan Allen, Ming Lu, Elizabeth Duus, Ruben Giorgino, Enrico Baroni
  • Neuroprotective compositions and their use
    Patent number: 10894029
    Abstract: Disclosed are compositions containing not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of memory impairment and cognitive dysfunction. More specifically, the invention discloses the use of abovementioned compositions for the management of cognitive impairment induced by chemotherapy and hyperglycemia.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 19, 2021
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
    Patent number: 10888555
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 12, 2021
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • Skin disinfectant composition
    Patent number: 10888535
    Abstract: It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: January 12, 2021
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Mari Shiozaki, Ryohei Tsubakiyama, Motoya Kikuchi, Kaoru Imai, Akifumi Hagi
  • Methods for treating Gaucher disease
    Patent number: 10888544
    Abstract: Methods for treating Gaucher disease in patients with renal or hepatic impairment.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 12, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Jing Li, M. Judith Peterschmitt, Vanaja Kanamaluru, Jun Chen, Sebastiaan J. M. Gaemers, Dan Rudin
  • Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
    Patent number: 10881634
    Abstract: The present invention provides a method for treatment or prevention of a disease associated with a decrease in bone mass comprising administering to a subject in need of such treatment a composition comprising an effective amount of genistein phosphate conjugate. The present invention also provides a method of improving bone architecture and bio-mechanical strength of bone comprising administering to a subject in need of such treatment of a composition comprising an effective amount of genistein phosphate conjugate. The present invention administering to a subject in need of such treatment a composition comprising an effective amount of genistein phosphate conjugate can effectively increase the oral bioavailability so as to reduce the symptoms and the risk of complications of menopausal women, increase bone mineral content, bone density and bio-mechanical strength of bone, and slow down osteoporosis.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: January 5, 2021
    Assignee: HUGHES BIOTECHNOLOGY CO., LTD
    Inventors: Shang-Ta Wang, Chen Hsu, Nan-Wei Su
  • Method for degrading bilirubin in skin
    Patent number: 10874600
    Abstract: A method of degrading bilirubin in skin is provided. The method involves identifying a target portion of skin where a reduction in bilirubin level is desired, and applying a vitamin B3-containing, low-pH composition to the target portion of skin during a treatment period. The composition contains an effective amount of a vitamin B3 compound, has a pH of less than 5.0, and reduces bilirubin level in the target portion of skin during the treatment period. The amount of vitamin B3 compound and the pH of the composition may be selected to provide a synergistic reduction in bilirubin level, as compared to the reduction in bilirubin level provided by the same composition at a neutral pH.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 29, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Tomohiro Hakozaki, Bin Fang Deyer
  • Compositions for treatment of dermatological diseases and conditions and methods of use thereof
    Patent number: 10869822
    Abstract: Compositions containing an effective dermatological disease-treating or dermatological condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle are disclosed. Methods of using the compositions are also disclosed.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 22, 2020
    Assignee: DermaMedics, LLC
    Inventor: Bryan B. Fuller
  • Bezafibrate for the treatment of cancer
    Patent number: 10857113
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
    Patent number: 10857149
    Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 8, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Svend Treppendahl, Heidi Lopez de Diego
  • Imidazopyridines Syk inhibitors
    Patent number: 10842803
    Abstract: Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 24, 2020
    Assignee: KRONOS BIO, INC.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Aaron C. Schmitt, Jianjun Xu, Zhongdong Zhao
  • Methods and compositions for wound healing
    Patent number: 10822317
    Abstract: The present invention relates to epoxy-tigliane compounds and their use in promoting wound healing. In particular embodiments, the epoxy-tigliane compounds are epoxy-tigliaen-3-one compounds. Methods of inducing or promoting wound healing as well as methods of reducing scarring and improving cosmetic outcomes upon healing of a wound are described. Compounds and compositions for use in wound healing are also described.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 3, 2020
    Assignee: QBIOTICS PTY LTD
    Inventors: Paul Warren Reddell, Victoria Anne Gordon, Ryan Moseley, Robert Steadman, Rachael Louise Moses, Glen Mathew Boyle, Peter Gordon Parsons
  • Compositions and methods for treating an infection
    Patent number: 10813908
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: October 27, 2020
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
    Patent number: 10813907
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with an therapeutically effective amount of an AED.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 27, 2020
    Assignee: ANAVEX LIFE SCINCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound
    Patent number: 10813865
    Abstract: The invention relates to a liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and a xanthine compound, and also to a cosmetic composition containing such a mixture. Use for caring for, making up and cleansing keratin materials.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 27, 2020
    Assignee: L'OREAL
    Inventors: Veronique Chevalier, Sofiane Ouattara
  • Combinatorial therapies of neurological disorders
    Patent number: 10799499
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinoline and baclofen and/or acamprosate.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: October 13, 2020
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirotchkin, Rodolphe Hajj
  • Spirocycle compounds and methods of making and using same
    Patent number: 10781211
    Abstract: Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: September 22, 2020
    Assignee: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
    Inventors: Daniel J. Buzard, Michael B. Shaghafi, Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Olivia D. Weber
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10752633
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser